Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Atreca Inc Cl A (BCEL)

Atreca Inc Cl A (BCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,566
  • Shares Outstanding, K 39,624
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,160 K
  • 60-Month Beta 1.03
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.33
Trade BCEL with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.97
  • Most Recent Earnings $-0.39 on 11/14/23
  • Next Earnings Date 06/19/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +185,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0750 +20.00%
on 06/07/24
0.1010 -10.89%
on 05/21/24
-0.0050 (-5.26%)
since 05/14/24
3-Month
0.0520 +73.08%
on 03/19/24
0.2000 -55.00%
on 03/15/24
-0.1090 (-54.77%)
since 03/14/24
52-Week
0.0520 +73.08%
on 03/19/24
1.2000 -92.50%
on 06/16/23
-1.0100 (-91.82%)
since 06/14/23

Most Recent Stories

More News
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer

Cellino Biotech, Inc. , an autonomous cell therapy technology platform company, today announced the expansion of its executive leadership team with the appointments of Abhijit (Abhi) Kulkarni, Ph.D. as...

BCEL : 0.0900 (-1.32%)
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer

SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Announces Corporate Reorganization to Extend Cash Runway

Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets Extends cash runway through 2023 and reduces workforce by more than...

BCEL : 0.0900 (-1.32%)
Atreca to Present at Upcoming Investor Conferences

SAN CARLOS, Calif., May 19, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments

SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”

SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca to Present at Upcoming Virtual Investor Conferences

SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing...

BCEL : 0.0900 (-1.32%)
Atreca Announces Expansion of Preclinical Pipeline

Atreca Announces Licensing Agreement with Zymeworks Atreca Declares EphA2-Targeting ADC (ATRC-301) as Clinical Candidate Virtual R&D Day scheduled...

BCEL : 0.0900 (-1.32%)

Business Summary

Atreca is a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types. While more traditional oncology drug discovery approaches attempt to generate antibodies against known targets, Atreca's approach...

See More

Key Turning Points

3rd Resistance Point 0.0983
2nd Resistance Point 0.0967
1st Resistance Point 0.0933
Last Price 0.0900
1st Support Level 0.0883
2nd Support Level 0.0867
3rd Support Level 0.0833

See More

52-Week High 1.2000
Fibonacci 61.8% 0.7615
Fibonacci 50% 0.6260
Fibonacci 38.2% 0.4905
Last Price 0.0900
52-Week Low 0.0520

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar